Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114,331,829
-
Number of holders
-
240
-
Total 13F shares, excl. options
-
96,474,919
-
Shares change
-
+228,917
-
Total reported value, excl. options
-
$5,644,897,783
-
Value change
-
+$10,118,846
-
Put/Call ratio
-
48%
-
Number of buys
-
113
-
Number of sells
-
-116
-
Price
-
$58.51
Significant Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q4 2021
302 filings reported holding FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share as of Q4 2021.
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) has 240 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 96,474,919 shares
of 114,331,829 outstanding shares and own 84.38% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (12,957,222 shares), ARK Investment Management LLC (10,312,167 shares), VANGUARD GROUP INC (7,675,787 shares), BlackRock Inc. (7,060,552 shares), PRICE T ROWE ASSOCIATES INC /MD/ (3,933,938 shares), Bellevue Group AG (3,775,736 shares), Casdin Capital, LLC (3,400,000 shares), JOHNSON & JOHNSON (3,379,064 shares), Capital World Investors (3,259,033 shares), and STATE STREET CORP (2,718,793 shares).
This table shows the top 240 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.